Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion type Assertion NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_head.
- NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion description "[In combination with paclitaxel, anti-PLK-1 siRNA chemosensitized non-small cell lung cancer (NSCLC) and prostate carcinoma cell lines, leading up to a 2-fold increase in the drug cytotoxic effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_provenance.
- NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion evidence source_evidence_literature NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_provenance.
- NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion SIO_000772 23531193 NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_provenance.
- NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion wasDerivedFrom befree-2016 NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_provenance.
- NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_assertion wasGeneratedBy ECO_0000203 NP1063751.RAuXYncFBNm21JT9Obyqv59V_z5F8R_oHtuTnBiF7eW88130_provenance.